ID   HL-60/5FU
AC   CVCL_YP33
DR   cancercelllines; CVCL_YP33
DR   Wikidata; Q94211538
RX   PubMed=31741260;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU).
CC   Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C9154; Adult acute myeloid leukemia
DI   ORDO; Orphanet_519; Acute myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0002 ! HL-60
SX   Female
AG   36Y
CA   Cancer cell line
DT   Created: 12-03-20; Last updated: 05-10-23; Version: 9
//
RX   PubMed=31741260; DOI=10.1007/s11033-019-05017-w;
RA   Dlugosz-Pokorska A., Pieta M., Janecki T., Janecka A.;
RT   "New uracil analogs as downregulators of ABC transporters in
RT   5-fluorouracil-resistant human leukemia HL-60 cell line.";
RL   Mol. Biol. Rep. 46:5831-5839(2019).
//